Diabetes educators call for tailored training to optimise Medtronic’s MiniMed 780G adoption

A new survey reveals that the main challenge in implementing Medtronic’s MiniMed 780G isn’t the device itself, but educating clinicians to manage patient expectations and complex nutrition, highlighting the need for region-specific, structured training programmes.

The hardest part of putting people onto Medtronic’s MiniMed 780G may not be teaching the buttons and menus, but explaining where the automation ends. A survey published in Advances in Therapy found that diabetes educators working across Africa, the Gulf, Central and Eastern Europe, Türkiye and Central Asia most often struggled with managing patient expectations, cited by 33.6 per cent of respondents. The same study found a second weakness in day-to-day food advice: only 56.1 per cent said they felt confident helping patients handle high-fat and high-protein meals, a stubborn problem for glucose control even with automated insulin delivery.

The research, listed by PubMed as having been published online on 30 July 2026, drew on a 23-question survey completed by all 82 educators invited between June and July 2025. It found broadly high confidence in the system overall, but also a cluster of practical teaching problems that go beyond pure technical knowledge. Explaining SmartGuard, the feature that automatically adjusts insulin delivery, was named as a challenge by 20.4 per cent. Others pointed to a lack of structured materials, trouble shooting alarms and teaching device settings. PubMed’s record also notes a conflict disclosure: lead author Tomader Ali has a consultancy agreement with Medtronic and sits on an Abbott advisory board, while the other authors declared no conflicts.

That matters because the survey did not appear in a vacuum. A 2024 Delphi consensus in Acta Diabetologica had already argued that diabetes educators needed a formal training route for the MiniMed 780G, saying existing diabetes technology guidance recommends automated insulin delivery but does not spell out what educators should know or how they should be trained. That panel brought together 11 experienced educators from 10 countries in Europe, the Middle East and Africa. On average they had 16.3 years of clinical experience and each was following at least 50 people using the system. They unanimously backed a structured pathway with mentorship and supervised in-field training, while 90 per cent supported face-to-face teaching backed by e-learning and education on the clinical evidence behind the device.

The new survey largely points in the same direction. When educators were asked what would most improve professional development, mentorship came top at 24.9 per cent, followed by stronger educator networks at 21.0 per cent. For accreditation, the leading choices were international certification bodies at 25.6 per cent and continuing education programmes at 20.3 per cent. The earlier consensus was more specific about what this should look like. It said a mentor should be a highly experienced educator embedded in a working diabetes technology service, capable of giving structured feedback, guiding case discussion and overseeing hands-on learning. Panel members eventually settled on at least two supervised in-field sessions, after observing one onboarding session and co-training another.

The full-text consensus paper also exposed a gap that helps explain the latest findings. Its proposed pathway concentrated on technical features and therapy management, but explicitly said it did not cover communication techniques or relational skills. Yet the new survey suggests those softer skills may be exactly where some of the biggest onboarding pressures lie, especially when users arrive expecting a fully automatic “artificial pancreas”. The consensus authors also warned that their model might not fit smaller centres with fewer resources, suggesting a hub-and-spoke approach may sometimes be needed. They said industry has a role in training, but ultimate responsibility should sit with the clinical team.

The reason this matters is that the MiniMed 780G has been promoted on the strength of long-term glucose results as well as convenience. In data presented by Medtronic at the European Association for the Study of Diabetes meeting in Vienna in September 2025, the company said records from 1,145 users aged 16 and over across Europe, the Middle East and Africa showed time in range rising to 78.6 per cent after initiation and staying broadly stable for 36 months. Medtronic also said autocorrection insulin delivery rose from zero to 12.9 per cent immediately and to 17.2 per cent by year three, while user-initiated delivery fell from 52.4 per cent to 41.5 per cent. Jennifer McVean, a senior medical affairs director at Medtronic Diabetes, said the findings showed the system could “improve diabetes care, providing lasting clinical and lifestyle advantages.”

Regional evidence shows why educators want more tailored preparation rather than generic pump training. A 2024 Ramadan study of 449 MiniMed 780G users from the Gulf found overall time in range of 70.7 per cent during the fasting month, with no increase in daytime hypoglycaemia and the best daytime control reaching 80.0 per cent. Night-time control was weaker, with time in range at 60.4 per cent and time above range higher after the evening meal pattern shifted. The authors said the algorithm adapted immediately to the change in routine. In Egypt, a separate 2023 study of 72 young people with type 1 diabetes used a five-day structured onboarding protocol in which continuous glucose monitoring began on day one, the pump started in manual mode for three days, and auto mode followed. After 84 days in auto mode, mean HbA1c fell from 8.72 per cent to 6.7 per cent, while time in range rose from 55.24 per cent to 81.7 per cent.

Taken together, the evidence suggests the bottleneck is not whether automated insulin delivery works, but whether health systems are building the teaching workforce needed to make it work well in ordinary life. The latest survey shows educators are mostly comfortable with the MiniMed 780G itself, yet less certain when the conversation turns to complex meals, realistic expectations, alarm handling and adaptation to local routines such as Ramadan. The earlier consensus offered a blueprint, but also acknowledged its own blind spots. The next step is likely to be less about adding more product training and more about creating consistent standards, stronger mentoring and region-specific teaching that treats education as clinical infrastructure rather than an afterthought.